4//SEC Filing
Readnour Robin Shane 4
Accession 0000950170-24-135150
CIK 0001880438other
Filed
Dec 9, 7:00 PM ET
Accepted
Dec 10, 8:46 PM ET
Size
16.3 KB
Accession
0000950170-24-135150
Insider Transaction Report
Form 4
Readnour Robin Shane
Director
Transactions
- Purchase
Common Stock
2024-12-06$1.45/sh+6,517$9,427→ 629,090 total(indirect: See Footnote) - Purchase
Common Stock
2024-12-09$1.43/sh+12,289$17,577→ 577,288 total(indirect: See Footnote) - Purchase
Common Stock
2024-12-10$1.49/sh+5,000$7,462→ 582,288 total(indirect: See Footnote) - Purchase
Common Stock
2024-12-10$1.49/sh+5,000$7,468→ 652,573 total(indirect: See Footnote) - Purchase
Common Stock
2024-12-06$1.45/sh+12,711$18,367→ 564,999 total(indirect: See Footnote) - Purchase
Common Stock
2024-12-09$1.43/sh+18,483$26,407→ 647,573 total(indirect: See Footnote)
Footnotes (9)
- [F1]This price represents the weighted average purchase price for multiple transactions reported on this line. The prices of the transactions reported on this line ranged from $1.40 to $1.45 per share. Upon request by the Commission staff, the issuer or a security holder of the issuer, the reporting person will undertake to provide full information regarding the number of shares sold at each separate price.
- [F2]MGC Venture Partners 2018 GP, LLC ("MGC 2018 GP") is the general partner of MGC Venture Partners 2018, LP ("MGC 2018 LP") and MGC Venture Partners QP 2018 LP ("MGC 2018 QP"). MGC 2018 GP has shared voting and shared dispositive power over the shares held by MGC 2018 LP and MGC 2018 QP. The Reporting Person is a member of the Issuer's board of directors and is a member of MGC 2018 QP and MGC 2018 LP and a managing partner of MGC 2018 GP and has shared voting power and shared dispositive power over the shares of common stock held by MGC 2018 LP and MGC 2018 QP. The Reporting Person disclaims beneficial ownership of the securities, except to the extent of such person's pecuniary interest in such securities.
- [F3]Shares held directly by MGC 2018 LP.
- [F4]This price represents the weighted average purchase price for multiple transactions reported on this line. The prices of the transactions reported on this line ranged from $1.435 to $1.45 per share. Upon request by the Commission staff, the issuer or a security holder of the issuer, the reporting person will undertake to provide full information regarding the number of shares sold at each separate price.
- [F5]Shares held directly by MGC 2018 QP.
- [F6]This price represents the weighted average purchase price for multiple transactions reported on this line. The prices of the transactions reported on this line ranged from $1.405 to $1.45 per share. Upon request by the Commission staff, the issuer or a security holder of the issuer, the reporting person will undertake to provide full information regarding the number of shares sold at each separate price.
- [F7]This price represents the weighted average purchase price for multiple transactions reported on this line. The prices of the transactions reported on this line ranged from $1.41 to $1.45 per share. Upon request by the Commission staff, the issuer or a security holder of the issuer, the reporting person will undertake to provide full information regarding the number of shares sold at each separate price.
- [F8]This price represents the weighted average purchase price for multiple transactions reported on this line. The prices of the transactions reported on this line ranged from $1.44 to $1.50 per share. Upon request by the Commission staff, the issuer or a security holder of the issuer, the reporting person will undertake to provide full information regarding the number of shares sold at each separate price.
- [F9]This price represents the weighted average purchase price for multiple transactions reported on this line. The prices of the transactions reported on this line ranged from $1.46 to $1.50 per share. Upon request by the Commission staff, the issuer or a security holder of the issuer, the reporting person will undertake to provide full information regarding the number of shares sold at each separate price.
Documents
Issuer
AN2 Therapeutics, Inc.
CIK 0001880438
Entity typeother
Related Parties
1- filerCIK 0001914883
Filing Metadata
- Form type
- 4
- Filed
- Dec 9, 7:00 PM ET
- Accepted
- Dec 10, 8:46 PM ET
- Size
- 16.3 KB